Clinical trial · Observational
Multi-Institutional Registry for Prostate Cancer Radiosurgery
Multi-Institutional Registry for Prostate Cancer Radiosurgery. An IRB Approved Observational Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To address pertinent questions regarding the utilization of stereotactic Body Radiotherapy (SBRT) to treat prostate cancer. The Florida Robotic Radiosurgery Association (FRRA) launched the first registry for prostate cancer patients treated with SBRT. The registry is designed to track surrogate treatment endpoints including prostate specific antigen (PSA), international prostate symptom score (IPSS),sexual health in men (SHIM), and visual analogue scale (VAS) scores, in addition to physical and survival data. Utilizing an independent vendor (Advertek, Inc.) experienced with the design and implementation of similar electronic registries, FRRA developed a data collection tool that staff members with a basic medical background can use to register and upload pertinent patient data, requiring no more than 20 to 30 minutes per patient. Participating patients will be monitored in follow-up for three years, with analysis and publication of the results semi-annually.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer Early Risk Treated by Radiosurgery | — | UNRESOLVED | — |
| Prostate Cancer Intermediate Risk Treated by Radiosurgery | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 5 years
Secondary outcomes (3)
- measure
- Treatment Outcomes
- timeFrame
- 5 years
- description
- Measurement of surrogate outcomes including IPSS and SHIM scores
- measure
- Treatment toxicity
- timeFrame
- 5 years
- description
- urinary and rectal complications as well as sexual health
- measure
- Assess biochemical disease free survival using PSA
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * pathological diagnosis of prostate cancer * early or intermediate risk Exclusion Criteria: * high risk prostate cancer
References
Publications (0)
Data not yet available